VENETOCLAX AND DELAYED RITUXIMAB WITH IBRUTINIB CONSOLIDATION AIMING AT UNDETECTABLE MINIMAL RESIDUAL DISEASE IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: VALUABLE TRIAL (SIE 2026) - Oct 6, 2026 - Abstract #DP032; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "In randomized trials, ven plus obinutuzumab (obi) led to higher uMRD rates and longer PFS than ven plus rituximab (R), but with more frequent severe, including fatal, infections. Four serious AE occurred (11.1%): wAIHA, ankle fracture, lung cancer G5, lower limb paresthesia. No tx-related deaths were reported.These results suggest that delayed R after ven improves BM uMRD4 rates beyond historical ven- R and ven-obi data, and MRD-guided ibr intensification fur- ther enhances outcomes with good tolerability."
Clinical • Minimal residual disease • Residual disease • Autoimmune Hemolytic Anemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lung Cancer • Musculoskeletal Diseases • Neutropenia • Solid Tumor • Thrombocytopenia
|
|
F. Martini1; S. Heltai2; R. Moia3; A. Visentin4; G. Quaresmini5; M. Varettoni6; G. Catania7; A. Ferrario8; L. Scarfò1,2; E. Albi1; E. Sant'Antonio1; E. Scarano1; P. Sportoletti9; L. Farina10; M. Motta11; L. Laurenti12; F. M. Quaglia13; A. M. Frustaci14; I. Del Giudice15; L. Calvo15; A. Cuneo16; G. M. Rigolin16; T. Musco2; C. Combi1; M. Colia1; P. Ghia1,2
|